Trial Profile
A Phase II Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Ifosfamide (Primary) ; Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jan 2013 New trial record